Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. announced a registered direct offering and a concurrent private placement that closed April 23, 2026. The company sold 16,129,033 shares of common stock together with 16,129,033 common warrants at a combined purchase price of $0.31 per share+warrant, generating gross proceeds of approximately $5.0 million prior to fees and expenses. H.C. Wainwright & Co. acted as exclusive placement agent.

Key Details

• Offering size and price: 16,129,033 shares + 16,129,033 common warrants; combined price $0.31; gross proceeds ≈ $5.0M (closed April 23, 2026).
• Warrant terms: common warrants exercisable at $0.31 per share beginning on the later of (a) stockholder approval to issue the warrant shares or (b) an increase in authorized shares (the “Initial Exercise Date”); expiration five years after the later of the Initial Exercise Date and the resale registration effectiveness. Exercise subject to 4.99% beneficial ownership cap (or 9.99% if elected).
• Placement agent economics: H.C. Wainwright receives 7.0% cash fee + 1.0% management fee of gross proceeds, reimbursement of expenses, and placement agent warrants to buy 1,129,032 shares (7% of shares sold) at $0.3875/share; similar fees/warrants apply on any cash exercise of common warrants.
• Warrant amendment: the company amended outstanding warrants (2,142,854 shares originally issued Jan 2025) held by an investor to reduce the exercise price from $2.26 to $0.31; those amended warrants become exercisable following stockholder approval and expire five years after such approval.
• Corporate actions required: the company will hold a shareholder meeting within 90 days after the offering to seek approvals to (i) issue shares on warrant exercise and (ii) increase authorized shares; it must file a resale registration statement for the warrant shares as soon as practicable (within five days of the effective date of the authorized‑share increase).

Why It Matters
This financing provides near‑term cash (about $5.0M before fees) for working capital and general corporate purposes, but it also creates potential dilution: up to 16.1M additional shares could be issued if the common warrants are exercised, plus placement agent warrants and the amended 2.14M‑share warrants at the lowered $0.31 strike. Issuance of those shares depends on shareholder approvals and an increase in authorized shares, so investors should watch the upcoming shareholder meeting, the resale registration filing, and any future exercises (which would also trigger placement agent fees and additional warrants). These are material items for share count, ownership percentages, and potential future capital inflows.